-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Allogene Therapeutics, Lowers Price Target to $4

Benzinga·05/15/2025 14:37:18
Listen to the news
Citigroup analyst Samantha Semenkow maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $8 to $4.